We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Ultra-Portable POC Molecular Diagnostics System to Instantly Detect Infectious Diseases

By HospiMedica International staff writers
Posted on 02 Feb 2024
Print article
Image: The Novel Dx device detects the genetic material of pathogens using NAAT (Photo courtesy of Novel Microdevices)
Image: The Novel Dx device detects the genetic material of pathogens using NAAT (Photo courtesy of Novel Microdevices)

Infectious diseases pose a significant threat to human health and have a substantial economic impact globally. Timely and accurate identification of pathogens is key for prompt treatment, improved patient outcomes, and halting the spread of diseases. Traditional pathogen detection methods are usually conducted in well-equipped clinical labs, relying on advanced equipment and specialized staff. Furthermore, pre-analytical steps such as lengthy transportation can skew results and extend turnaround times (TAT), hindering effective control of infectious diseases, especially in areas with limited resources. Now, a rapid RT-PCR platform being developed to provide highly accurate, rapid, and affordable diagnoses of infectious diseases at point-of-care and near-patient settings could enable immediate treatment initiation and curtail potential disease transmission.

Novel Microdevices (Baltimore, MD, US) is advancing its affordable, portable, rapid, multiplex, and user-friendly PCR testing solution for infectious diseases. This innovative technology simplifies complex scientific processes, typically carried out in high-complexity labs, into a compact device. Point-of-care diagnostics offered by the Novel Dx device allow for immediate results, enabling prompt action instead of the extended waiting times associated with traditional laboratory tests. The Novel Dx device employs Nucleic Acid Amplification Techniques (NAAT), which is the same method used in clinical reference laboratories, to detect the genetic material of pathogens.

The Novel Dx molecular testing platform utilizes polymerase chain reaction (PCR) technology in a disposable cartridge. The patient's sample is added to this cartridge, which is then inserted into the Novel Dx system. The system analyzes genetic sequences to identify diseases and detect genetic mutations that may make bacteria resistant to antibiotics. Novel Dx is capable of providing lab-quality results in less than 15 minutes, allowing patients to be tested, diagnosed, and treated all within a single visit, thus eliminating the wait for results from more complex labs. Designed for portability and weighing just four pounds, the Novel Dx diagnostic tool is battery-operated, making it especially suitable for use in low-resource settings and low-and middle-income countries (LMICs).

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
12-Channel ECG
CM1200B
New
Pediatric Phlebotomy Chair
2665M2 Extra Wide Pediatric Phlebotomy Chair
New
Electrocardiograph
BeneHeart R700/R900

Print article

Channels

Surgical Techniques

view channel
Image: The Trilogy Valve with locator technology is the only TAVI system approved for aortic regurgitation (Photo courtesy of JenaValve)

New Transcatheter Valve Found Safe and Effective for Treating Aortic Regurgitation

Aortic regurgitation is a condition in which the aortic valve does not close properly, allowing blood to flow backward into the left ventricle. This results in decreased blood flow from the heart to the... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.